MAGEC3: A Potential Drug Target and Biomarker for the MAGE Family

Target Name: MAGEC3

NCBI ID: G139081

MAGEC3

MAGEC3: A Potential Drug Target and Biomarker for the MAGE Family

The MAGE family is a well-established superfamily of cytotoxic T-cells that play a crucial role in immune surveillance and cancer progression. MAGE1, MAGE2, and MAGE3 are involved in the production of agonizing pain and inflammation, while MAGE4 and MAGE5 are involved in the regulation of cell death. The discovery of MAGEC3, a novel member of the MAGE family, has significant implications for our understanding of this family and its potential as a drug target.

MAGEC3 is a 21-kDa protein that is expressed in various tissues, including the brain, spleen, and thymus. It is characterized by a unique N-terminal region that contains a conserved glycosylation site and a variable C-terminal region that is unique among MAGE family members. MAGEC3 has been shown to induce cell death in various cell types, including cancer cells, and to display agonizing pain-like behaviors in mice.

The unique structure of MAGEC3 and its ability to induce cell death make it an attractive drug target. MAGEC3 has been shown to be involved in cell signaling pathways, including the production of reactive oxygen species (ROS) and the regulation of cell apoptosis. It is also involved in the production of pro-inflammatory cytokines, such as IL-1尾, and in the regulation of immune cell function.

In addition to its potential as a drug target, MAGEC3 also has the potential to serve as a biomarker for cancer diagnosis and treatment. The agonizing pain and inflammation that MAGEC3 is involved in can be used as a subjective indicator of disease severity, making it a valuable tool for monitoring the effectiveness of cancer treatments.

MAGEC3 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as the production of angiin, a critical component of blood vessels that can promote tumor growth. The inhibition of MAGEC3 has been shown to inhibit the production of angiin and to have a negative impact on tumor growth.

In conclusion, MAGEC3 is a novel and promising drug target and biomarker for the MAGE family. Its unique structure and function make it an attractive target for small molecule inhibitors, antibodies, or other therapeutic approaches. Further research is needed to fully understand the mechanisms of MAGEC3 and its potential as a drug and biomarker.

Protein Name: MAGE Family Member C3

The "MAGEC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets